摘要
目的:研究阿司匹林对不稳定型心绞痛(UAP)治疗效果及血清M-CSF、CK-MB、sICAM-1水平变化分析。方法:选择2014年2月至2016年4月在我院进行治疗的UAP患者60名,按照不同的治疗方法分为观察组和对照组。对照组使用常规方法治疗,观察组在对照组基础上联合阿司匹林口服药物治疗。采用酶联免疫吸附法测定血清M-CSF、CK-MB、sICAM-1水平变化,对M-CSF、sICAM-1水平采用TMI危险积分进行判定并观察两组患者治疗后的临床疗效。结果:治疗后,观察组不良反应发生率为13.33%,而对照组不良反应发生率为46.67%差异显著(P<0.05);治疗后,观察组的外周血M-CSF、sICAM-1、CK-MB水平,明显低于对照组外周血水平,差异显著(P<0.05),治疗后观察组的TMI危险积分随外周血M-CSF、sICAM-1水平升高,且对比对照组水平显著差异(P<0.05)。结论:阿司匹林能够有效抑制UAP患者的冠状动脉粥样硬化的风险,且能有效改善外周血清M-CSF、CK-MB、sICAM-1水平,M-CSF、CK-MB、sICAM-1三种指标是评估UAP患者的重要参考指标。
Objective：To study the therapeutic effect of aspirin on UAP patients and the changes of serum levels of M-CSF,CK-MB and sICAM-1.Methods：60 patients with UAP who were treated in hospital from February 2014 to April 2016 were selected and randomly divided into the control group and the observation group.The patients in the control group were treated with routine treatment,while the patients in the observation group were treated with aspirin on the basis of the control group.Then the serum levels of M-CSF,CK-MB and sICAM-1 were measured by enzyme-linked immunosorbent assay （ELISA） and determined by TMI risk score.Results：After treatment,the incidence of adverse reactions in the observation group was 13.33%,which was lower than 46.67% in the control group （P〈0.05）.After treatment,the levels of peripheral blood M-CSF,sICAM-1 and CK-MB in the observation group were significantly lower than those of the control group （P〈0.05）.The TMI risk score of the observation group was significantly higher than that of the control group （P〈0.05）;After treatment,the levels of plasma miRNA in the observation group was significantly higher than that of the control group （P〈0.05）.Conclusion：Aspirin can effectively inhibit the risk of coronary atherosclerosis in UAP patients and improve the levels of peripheral blood M-CSF,CK-MB and sICAM-1,while M-CSF,CK-MB and sICAM-1 are the important reference for assessing UAP.
出处
《现代生物医学进展》
CAS
2017年第21期4135-4138,共4页
Progress in Modern Biomedicine
基金
辽宁省科技厅计划项目(2013226012)
关键词
阿司匹林
SICAM-1
UAP
M-C SF
CK-MB
Aspirin
UAP
M-CSF
CK-MB
